SAN DIEGO--(BUSINESS WIRE)--Stemson Therapeutics today announced a major technological advance that clears the path for its proprietary hair rejuvenation solution to advance toward human clinical trials. Stemson is developing an iPSC-derived autologous cell therapy to regenerate healthy hair follicles and has successfully created human hair follicles in humanized mice using engineered follicular units.

圣地亚哥--（商业新闻短讯）--斯特姆森治疗公司今天宣布了一项重大技术进步，为其专有的头发再生解决方案开辟了通往人体临床试验的道路。斯特姆森正在开发一种iPSC衍生的自体细胞疗法，以再生健康的毛囊，并使用工程卵泡单位在人源化小鼠中成功创建了人类毛囊。

The engineered follicular units are designed to provide an unlimited source of hair follicle replacements capable of treating a range of hair loss indications, including Androgenetic Alopecia, Scarring Alopecia, and Chemo-Induced Alopecia..

工程卵泡单位旨在提供无限的毛囊替代物来源，能够治疗一系列脱发指征，包括雄激素性脱发，瘢痕性脱发和化学诱导的脱发。。

An estimated 80 million people in the United States experience hair loss, which is often associated with emotional distress leading to reduced quality of life, anxiety, and depression. Despite the $10 billion market for hair loss today, there are no existing therapeutic solutions capable of rejuvenating shrinking follicles, nor any that generate new hair follicles to replace lost hair..

据估计，美国有8000万人脱发，这通常与情绪困扰有关，导致生活质量下降，焦虑和抑郁。尽管目前脱发市场价值100亿美元，但目前还没有能够使萎缩的毛囊恢复活力的治疗方案，也没有产生新的毛囊来替代脱落的头发。。

“Stemson’s engineered follicular units will be the first therapeutic solution capable of replacing lost hair follicles, a breakthrough sorely needed to treat people suffering from many forms of hair loss,” says Geoff Hamilton, Chief Executive Officer of Stemson. “The recent demonstration of robust and reproducible all-human hair growth in humanized mice is a strong indicator of potential success in human trials.”.

斯特姆森首席执行官杰夫·汉密尔顿（GeoffHamilton）表示：“斯特姆森的工程卵泡单位将是第一个能够替代失去的毛囊的治疗方案，这是治疗多种形式脱发患者迫切需要的突破。”。“最近在人源化小鼠中显示出强大且可重复的全人类毛发生长，这是人体试验潜在成功的有力指标。”。

Engineered follicular units are constructed through a proprietary bioprinting process which combines hair follicle cells and biomaterials into a three dimensional biomimetic design resembling the hair follicle shape. Upon transplantation, the engineered follicular units will engraft with the host skin and develop into mature natural hair follicles replacing those that have been lost.

工程卵泡单元是通过专有的生物打印过程构建的，该过程将毛囊细胞和生物材料结合成类似毛囊形状的三维仿生设计。移植后，工程化的毛囊单位将与宿主皮肤植入，并发育成成熟的天然毛囊，替代那些已经丢失的毛囊。

The design of the engineered follicular units enables handling and precision delivery into the skin using common hair transplantation tools and techniques available in the field today. In addition, the design facilitates healthy follicle development with proper directionality and emergence of a hair shaft out of the skin..

工程滤泡单元的设计能够使用当今领域可用的常见毛发移植工具和技术进行处理并精确输送到皮肤中。此外，该设计有助于健康的毛囊发育，具有正确的方向性，并使毛干从皮肤中出现。。

To support the company’s growth and advancement toward human clinical trials, Stemson has promoted Meghan Samberg, PhD, to Chief Development Officer, and Nick Wisniewski, PhD, to Vice President of Data Science & Bioinformatics. The promotions move Stemson firmly into the final stages of product development with an emphasis on leveraging bioengineering, big data, and machine learning approaches to create a highly controlled and reproducible therapeutic outcome for hair growth..

为了支持公司在人类临床试验方面的发展和进步，斯特姆森将梅根·桑伯格（MeghanSamberg）博士提升为首席开发官，将尼克·维斯涅夫斯基（NickWisniewski）博士提升为数据科学与生物信息学副总裁。这些促销活动使斯特姆森坚定地进入了产品开发的最后阶段，重点是利用生物工程、大数据和机器学习方法，为头发生长创造高度可控和可重复的治疗效果。。

“Stemson is poised to deliver truly novel and effective hair growth treatments to hair loss patients. Our recent results in mice engrafted with human skin show a therapeutic solution to hair loss is within our sights,” stated Dr. Samberg. “In 2019, Stemson founder Alexey Terskikh, PhD, demonstrated functional hair follicle cells grown from human stem cells can grow hair when combined with mouse cells and transplanted in mouse skin.

桑伯格博士说：“斯特姆森准备为脱发患者提供真正新颖有效的毛发生长疗法。我们最近在植入人体皮肤的小鼠身上取得的结果表明，脱发的治疗方案在我们的视线之内。”。2019年，Stemson创始人Alexey Terskikh博士证明，人类干细胞生长的功能性毛囊细胞与小鼠细胞结合并移植到小鼠皮肤中后可以长出头发。

Since then, Stemson’s development team has focused on demonstrating that an all-human bioengineered cell solution can generate brand new human hair follicles in human skin, which gives us much higher confidence the product may work in human patients. Now that we have achieved that milestone, I am excited to move us forward into the final development before testing in human trials.”.

从那时起，斯特姆森的开发团队一直致力于证明全人类生物工程细胞解决方案可以在人体皮肤中产生全新的人类毛囊，这使我们对该产品可能在人类患者中起作用有了更高的信心。现在我们已经实现了这一里程碑，我很高兴在进行人体试验之前将我们推进到最终开发。”。

“Engineering follicular units derived from Induced Pluripotent Stem Cells is a highly promising but complex approach to solve hair loss,” added Dr. Wisniewski. “As a core part of our product development strategy at Stemson, we are investing in big data generation and cutting-edge analytics, using machine learning algorithms to manage the biological complexity and generate consistent high quality results.”.

Wisniewski博士补充道：“从诱导性多能干细胞衍生的工程卵泡单位是一种非常有前途但复杂的解决脱发的方法。”。“作为斯特姆森产品开发战略的核心部分，我们正在投资大数据生成和尖端分析，使用机器学习算法来管理生物复杂性并产生一致的高质量结果。”。

For updates on Stemson’s progress and advancement, please visit www.stemson.com.

有关Stemson进展和进步的最新信息，请访问www.Stemson.com。

About Stemson Therapeutics

关于Stemson Therapeutics

Stemson Therapeutics is a pre-clinical stage cell therapy company founded in 2018 with a mission to cure hair loss by leveraging the regenerative power of Induced Pluripotent Stem Cells. Stemson uses iPSC to regenerate the critical cells required to grow hair and which are damaged or depleted in patients suffering from hair loss.

Stemson Therapeutics是一家成立于2018年的临床前阶段细胞治疗公司，其使命是通过利用诱导多能干细胞的再生能力来治疗脱发。斯特姆森使用iPSC再生生长头发所需的关键细胞，这些细胞在脱发患者中受损或耗尽。

The iPSC-derived cells are used to grow de novo hair follicles, offering a new supply of hair to treat people suffering from various forms of Alopecia. Today, there are no available treatments capable of growing new hair follicles. Stemson’s world class team of scientists, advisors and collaborators are passionate about delivering a scientifically based, clinically tested cure for hair loss to the millions of hair loss sufferers who seek help for their hair loss condition.

iPSC衍生的细胞用于从头生长毛囊，为治疗各种形式的脱发患者提供新的头发供应。今天，没有可用的治疗方法能够生长新的毛囊。斯特姆森的世界级科学家、顾问和合作者团队热衷于为数百万寻求脱发帮助的脱发患者提供一种基于科学、经过临床测试的脱发治疗方法。

Stemson Therapeutics is headquartered in San Diego, CA. For more information, please visit www.stemson.com..

Stemson Therapeutics总部位于加利福尼亚州圣地亚哥。有关更多信息，请访问www.Stemson.com。。